Read More

Outset Medical Reports Unaudited Q4 And 2023 Revenue, Provides 2024 Revenue And Non-GAAP Gross Margin Guidance; Q4 Revenue Totaled $30.5M Vs $30.13M Est.; Sees FY23 Revenue $130M Vs $130.01M Est.; Sees FY24 Revenue $145M-$153M Vs $149.06M Est.

Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis,today reported unaudited revenue for the fourth quarter

OM